Northview Acquisition registerred with the SEC to offer 18 million units at $10 each. A unit consists of one share of common stock and one-half of one redeemable warrant, with whole warrants exercisable at $11.50.
I-Bankers Securities is sole book-running manager for the offering. The underwriters have a 30-day option to purchase up to an additional 2.7 million units to cover over-allotments, if any.
The SPAC expects to target small-cap healthcare companies that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space.
Northview is led by Co-Founder, Director and CEO Jack Stover, who was previously president and CEO of Interpace Biosciences.
The SPAC intends to apply for a Nasdaq listing but has not yet selected a ticker symbol.
